Your request to link to rcsb for BDBM22597
- 6C7Y: crystal structure of inhibitory protein socs1 in complex with jak1 kinase domain (10.1038/S41467-018-04013-1 )
- 6E8I: legionella longbeachae lesh (llo2327) bound to phosphotyrosine (10.1038/S41467-018-06943-2 )
- 3R7O: structure of dually phosphorylated c-met receptor kinase in complex with an mk-2461 analog 09-jan-13 3r7o 1 hetsyn title (10.1074/JBC.M110.204404 )
- 4E6D: jak2 kinase (jh1 domain) triple mutant in complex with compound 7 13-jun-12 4e6d 1 title (10.1021/JM300438J )
- 5AUL: pi3k p85 c-terminal sh2 domain/cd28-derived peptide complex (10.1074/JBC.M116.755173 )
- 2LDR: solution structure of helix-ring domain of cbl-b in the tyr363 phosphorylated form (10.1073/PNAS.1110712108 )
- 5O76: structure of phosphoy371 c-cbl in complex with zap70-peptide and ubv.pcbl ubiquitin variant (10.1016/J.MOLCEL.2017.09.027 )
- 2QYQ: human raf kinase inhibitor protein (rkip) in complex with o- phosphotyrosine
- 1FMK: crystal structure of human tyrosine-protein kinase c-src (10.1038/385595A0 )
- 3TU7: human alpha-thrombin complexed with n-(methylsulfonyl)-d-phenylalanyl- n-((1-carbamimidoyl-4-piperidinyl)methyl)-l-prolinamide (bms-189664)
- 6FEK: oncogenic point mutation of ret receptor tyrosine kinase (10.1038/S41467-018-02994-7 )
- 3C7Q: structure of vegfr2 kinase domain in complex with bibf1120 (10.1158/0008-5472.CAN-07-6307 )
- 2ZM4: crystal structure of imidazo quinoxaline 1 bound to the kinase domain of human lck, activated form (auto- phosphorylated on tyr394) (10.1016/J.BMC.2008.10.041 )
- 2ZM3: complex structure of insulin-like growth factor receptor and isoquinolinedione inhibitor (10.1016/J.BMCL.2008.04.044 )
- 2ZM1: crystal structure of imidazo pyrazin 1 bound to the kinase domain of human lck, (auto-phosphorylated on tyr394) (10.1016/J.BMC.2008.10.041 )
- 1G1H: crystal structure of protein tyrosine phosphatase 1b complexed with a bis-phosphorylated peptide (etd(ptr)(ptr) rkggkgll) from the insulin receptor kinase (10.1016/S1097-2765(00)00137-4 )
- 3IO7: 2-aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of jak2 (10.1016/J.BMCL.2009.10.053 )
- 3IOK: 2-aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of jak2 (10.1016/J.BMCL.2009.10.053 )
- 2EU0: the nmr ensemble structure of the itk sh2 domain bound to a phosphopeptide (10.1016/J.JMB.2005.12.073 )
- 1KA6: sap/sh2d1a bound to peptide n-py (10.1093/EMBOJ/21.3.314 )
- 4F08: discovery and optimization of c-2 methyl imidazo-pyrrolopyridines as potent and orally bioavailable jak1 inhibitors with selectivity over jak2 (10.1021/JM300628C )
- 2OFU: x-ray crystal structure of 2-aminopyrimidine carbamate 43 bound to lck (10.1021/JM060435I )
- 3VRZ: crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor 1-[4-(4-amino-7-cyclopentyl-7h-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]- 3-benzylurea (10.1126/SCITRANSLMED.3004387 )
- 3VRO: crystal structure of the tyrosine kinase binding domain of cbl-c in complex with phospho-src peptide (10.1093/JB/MVS085 )
- 3PX7: crystal structure of covalent complex of topoisomerase 1a with substrate
- 3S8N: crystal structure of the grb2 sh2 domain in complex with a pyxn- derived tripeptide (10.1021/JA2068752 )
- 3S8O: crystal structure of the grb2 sh2 domain in complex with a pyxn- derived tripeptide (10.1021/JA2068752 )
- 3S8L: protein-ligand interactions: thermodynamic effects associated with increasing hydrophobic surface area (10.1021/JA2068752 )
- 4ZJV: crystal structure of egfr kinase domain in complex with mitogen- inducible gene 6 protein (10.1038/NSMB.3074 )
- 4NCT: human dyrk1a in complex with pkc412 (10.1107/S1399004715005106 )
- 6UWY: dyrk1a bound to a harmine derivative (10.1021/ACS.JMEDCHEM.9B01379 )
- 2AUH: crystal structure of the grb14 bps region in complex with the insulin receptor tyrosine kinase (10.1016/J.MOLCEL.2005.09.001 )
- 5AMN: the discovery of 2-substituted phenol quinazolines as potent and selective ret kinase inhibitors (10.1016/J.EJMECH.2016.01.039 )
- 2ROR: solution structure of the vav1 sh2 domain complexed with a tyrosine-phosphorylated peptide from slp76
- 6HK3: crystal structure of gsk-3b in complex with pyrazine inhibitor c44 (10.1021/ACS.JCTC.9B00104 )
- 6HK7: crystal structure of gsk-3b in complex with pyrazine inhibitor c50 (10.1021/ACS.JCTC.9B00104 )
- 6HK4: crystal structure of gsk-3b in complex with pyrazine inhibitor c22 (10.1021/ACS.JCTC.9B00104 )
- 4TRL: structure of ephrin type-a receptor 2
- 5U1M: structure of the irs-1 ptb domain bound to the juxtamembrane region of the insulin receptor (10.1038/NCOMMS14892 )
- 1P13: crystal structure of the src sh2 domain complexed with peptide (sdpyanfk) (10.1021/BI0340503 )
- 4S0G: crystal structure of ptpn3 (ptph1) in complex with eps15 ptyr849 p850v peptide (10.1016/J.STR.2015.01.017 )
- 2H5K: crystal structure of complex between the domain-swapped dimeric grb2 sh2 domain and shc-derived ligand, ac-nh-ptyr-val-asn-nh2 (10.1016/J.ABB.2007.03.010 )
- 5HEZ: jak2 kinase (jh1 domain) mutant p1057a in complex with tg101209 (10.1126/SCITRANSLMED.AAG1974 )
- 5KPK: glycogen synthase kinase 3 beta complexed with brd0209 (10.1126/SCITRANSLMED.AAM8460 )
- 5KPM: glycogen synthase kinase 3 beta complexed with brd3731 (10.1126/SCITRANSLMED.AAM8460 )
- 1A1C: c-src (sh2 domain) complexed with ace-phosphotyr-glu-(n-me(-(ch2)3- cyclopentyl)) (10.1021/BI970019N )
- 1A1B: c-src (sh2 domain) complexed with ace-phosphotyr-glu-(n,n-dipentyl amine) (10.1021/BI970019N )
- 1A1E: c-src (sh2 domain) complexed with ace-phosphotyr-glu-(3- butylpiperidine) (10.1021/BI970019N )
- 2PVF: crystal structure of tyrosine phosphorylated activated fgf receptor 2 (fgfr2) kinase domain in complex with atp analog and substrate peptide (10.1016/J.MOLCEL.2007.06.028 )
- 2HCK: src family kinase hck-quercetin complex (10.1038/385602A0 )
- 4XLV: crystal structure of the activated insulin receptor tyrosine kinase dimer (10.1038/NCOMMS7406 )
- 1YI6: c-term tail segment of human tyrosine kinase (258-533)
- 6KC4: crystal structure of human fer sh2 domain bound to a phosphopeptide (depyenvd) (10.1002/PRO.3713 )
- 1RR8: structural mechanisms of camptothecin resistance by mutations in human topoisomerase i (10.1016/J.JMB.2004.03.077 )
- 2Y1N: structure of c-cbl-zap-70 peptide complex (10.1038/NSMB.2231 )
- 4E5W: jak1 kinase (jh1 domain) in complex with compound 26 (10.1021/JM300438J )
- 6E8K: legionella longbeachae lesh (llo2327) bound to the human interleukin-2 receptor beta ptyr387 peptide (10.1038/S41467-018-06943-2 )
- 5D39: transcription factor-dna complex (10.1073/PNAS.1611228113 )
- 6K0J: the co-crystal structure of dyrk2 with a small molecule inhibitor (10.1073/PNAS.1912033116 )
- 6F3F: autoinhibited src kinase bound to adp (10.1038/S41598-017-17703-5 )
- 1FHR: solution structure of the fha2 domain of rad53 complexed with a phosphotyrosyl peptide (10.1006/JMBI.2000.4095 )
- 6UIP: dyrk1a kinase domain in complex with a 6-azaindole derivative, gnf2133. (10.1021/ACS.JMEDCHEM.9B01624 )
- 1PTU: crystal structure of protein tyrosine phosphatase 1b complexed with phosphotyrosine-containing hexa-peptide (dadepyl-nh2)
- 6I83: crystal structure of phosphorylated ret v804m tyrosine kinase domain complexed with pdd00018366 (10.1021/ACSMEDCHEMLETT.9B00615 )
- 6I82: crystal structure of partially phosphorylated ret v804m tyrosine kinase domain complexed with pdd00018412 (10.1021/ACSMEDCHEMLETT.9B00615 )
- 6P8F: crystal structure of cdk4 in complex with cyclind1 and p27 (10.1126/SCIENCE.AAW2106 )
- 2VX3: crystal structure of the human dual specificity tyrosine- phosphorylation-regulated kinase 1a (10.1016/J.STR.2013.03.012 )
- 3ZEP: crystal structure of jak3 kinase domain in complex with a pyrrolopyrazine-2-phenyl ether inhibitor (10.1016/J.BMCL.2013.03.015 )
- 3ZEW: crystal structure of ephb4 in complex with staurosporine (10.1002/PRO.2445 )
- 4QSY: shp2 sh2 domain in complex with gab1 peptide
- 4RXZ: crystal structure of mdmx phosporylated tyr99 in complex with a 12-mer peptide (10.1038/ONC.2015.255 )
- 6NE7: structure of g810a mutant of ret protein tyrosine kinase domain. (10.1074/JBC.RA119.007682 )
- 2X2L: crystal structure of phosphorylated ret tyrosine kinase domain with inhibitor (10.1016/J.BMC.2010.01.011 )
- 2X2M: crystal structure of phosphorylated ret tyrosine kinase domain with inhibitor (10.1016/J.BMC.2010.01.011 )
- 2X2K: crystal structure of phosphorylated ret tyrosine kinase domain with inhibitor (10.1016/J.BMC.2010.01.011 )
- 6ELR: human jak1 kinase domain in complex with compound 7
- 4PY1: crystal structure of tyk2 in complex with compound 15, 6-((2,5- dimethoxyphenyl)thio)-3-(1-methyl-1h-pyrazol-4-yl)-[1,2,4]triazolo[4, 3-b]pyridazine (10.1016/J.BMCL.2014.07.052 )
- 2LQW: solution structure of phosphorylated crkl (10.1038/NCHEMBIO.954 )
- 2LJD: monophosphorylated (747py) beta3 integrin cytoplasmic tail under membrane mimetic conditions (10.1074/JBC.M111.231951 )
- 2LJE: biphosphorylated (747py, 759py) beta3 integrin cytoplasmic tail under membrane mimetic conditions (10.1074/JBC.M111.231951 )
- 2LJF: monophosphorylated (747py) beta3 integrin cytoplasmic tail under aqueous conditions (10.1074/JBC.M111.231951 )
- 5MJA: kinase domain of human ephb1 bound to a quinazoline-based inhibitor (10.1021/ACSCHEMBIO.6B01083 )
- 5MJB: kinase domain of human ephb1, g703c mutant, covalently bound to a quinazoline-based inhibitor (10.1021/ACSCHEMBIO.6B01083 )
- 4IVC: jak1 kinase (jh1 domain) in complex with the inhibitor (trans-4-{2- [(1r)-1-hydroxyethyl]imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6h)- yl}cyclohexyl)acetonitrile (10.1021/JM4004895 )
- 4IVB: jak1 kinase (jh1 domain) in complex with the inhibitor trans-4-{2- [(1r)-1-hydroxyethyl]imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6h)- yl}cyclohexanecarbonitrile (10.1021/JM4004895 )
- 4IVA: jak2 kinase (jh1 domain) in complex with the inhibitor trans-4-[(8as)- 2-[(1r)-1-hydroxyethyl]imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(8ah)- yl]cyclohexanecarbonitrile (10.1021/JM4004895 )
- 2I6O: crystal structure of the complex of the archaeal sulfolobus ptp-fold phosphatase with phosphopeptides n-g-(p)y-k-n (10.1002/PROT.21262 )
- 6HDR: human dyrk2 bound to curcumin
- 6HDP: human dyrk2 bound to scorzodihydrostilbene a
- 4YU2: crystal structure of dyrk1a with harmine-derivatized annh-75 inhibitor (10.3390/MOLECULES25245962 )
- 3TKZ: structure of the shp-2 n-sh2 domain in a 1:2 complex with rvipyfvplnr peptide (10.1021/BI200439V )
- 1P4E: flpe w330f mutant-dna holliday junction complex (10.1074/JBC.M300853200 )
- 3L4K: topoisomerase ii-dna cleavage complex, metal-bound (10.1038/NATURE08974 )
- 3L4J: topoisomerase ii-dna cleavage complex, apo (10.1038/NATURE08974 )
- 3EB0: crystal structure of cgd4_240 from cryptosporidium parvum in complex with indirubin e804
- 5HKZ: crystal structure of c-cbl tkbd in complex with spry2 peptide (36-60, py55) refined to 1.8 a resolution (p21 form)
- 5HKY: crystal structure of c-cbl tkbd domain in complex with spry2 peptide (36-60, py55) refined to 1.8a resolution (p6 form)
- 4MQ2: the crystal structure of dyrk1a with a bound pyrido[2,3-d]pyrimidine inhibitor (10.1016/J.BMCL.2013.10.055 )
- 4MQ1: the crystal structure of dyrk1a with a bound pyrido[2,3-d]pyrimidine inhibitor (10.1016/J.BMCL.2013.10.055 )
- 6P5S: hipk2 kinase domain bound to cx-4945 (10.1074/JBC.RA119.009725 )
- 3Q6W: structure of dually-phosphorylated met receptor kinase in complex with an mk-2461 analog with specificity for the activated receptor (10.1074/JBC.M110.204404 )
- 2HDX: crystal structure of the src homology-2 domain of sh2-b in complex with jak2 ptyr813 phosphopeptide (10.1016/J.JMB.2006.05.070 )
- 6DBN: jak1 with compound 23 (10.1021/ACS.JMEDCHEM.8B00917 )
- 6DBK: tyk2 with compound 8 (10.1021/ACS.JMEDCHEM.8B00917 )
- 6C5X: crystal structure of socs1 in complex with elonginb and elonginc (10.1038/S41467-018-04013-1 )
- 2V7A: crystal structure of the t315i abl mutant in complex with the inhibitor pha-739358 (10.1158/0008-5472.CAN-07-1825 )
- 3N8M: crystal structure of the grb2 sh2 domain in complex with an acyclic ligand having the sequence pyvnvp (10.1021/ML100142Y )
- 3N84: crystal structure of the grb2 sh2 domain in complex with a 23-membered macrocyclic ligand having the sequence pyvnvp (10.1021/ML100142Y )
- 3AD4: crystal structure of methoxy benzofuran derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
- 3AD5: crystal structure of triazolone derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
- 3AD6: crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
- 4GPL: structure of cbl(tkb) bound to a phosphorylated pentapeptide (10.1038/SREP01639 )
- 1YVL: structure of unphosphorylated stat1 (10.1016/J.MOLCEL.2005.02.021 )
- 1YVH: crystal structure of the c-cbl tkb domain in complex with the aps ptyr-618 phosphopeptide (10.1074/JBC.M414157200 )
- 4ICZ: her2 1221/1222 phosphorylation regulated by ptpn9
- 4GL9: crystal structure of inhibitory protein socs3 in complex with jak2 kinase domain and fragment of gp130 intracellular domain (10.1038/NSMB.2519 )
- 6S1H: crystal structure of dyrk1a with small molecule inhibitor
- 1AD5: src family kinase hck-amp-pnp complex (10.1038/385602A0 )
- 4ROJ: crystal structure of the vav2 sh2 domain in complex with txnip phosphorylated peptide
- 6I5J: crystal structure of socs2:elongin c:elongin b in complex with growth hormone receptor peptide (10.1038/S41467-019-10190-4 )
- 6I5N: crystal structure of socs2:elongin c:elongin b in complex with growth hormone receptor peptide (10.1038/S41467-019-10190-4 )
- 3OMH: crystal structure of ptpn22 in complex with skap-hom ptyr75 peptide (10.1074/JBC.M111.254722 )
- 5MQS: sialidase bt_1020 (10.1038/NATURE21725 )
- 5MQR: sialidase bt_1020 (10.1038/NATURE21725 )
- 6PK6: human prpf4b bound to benzothiophene inhibitor 329
- 3KMM: structure of human lck kinase with a small molecule inhibitor
- 3GB2: gsk3beta inhibitor complex (10.1021/JM900647E )
- 2L4K: water refined solution structure of the human grb7-sh2 domain in complex with the 10 amino acid peptide py1139
- 1KSW: structure of human c-src tyrosine kinase (thr338gly mutant) in complex with n6-benzyl adp (10.1016/S1074-5521(02)00091-1 )
- 3KVW: crystal structure of dual-specificity tyrosine phosphorylation regulated kinase 2 (dyrk2) in complex with an indirubin ligand
- 3N7Y: crystal structure of the grb2 sh2 domain in complex with a 20-membered macrocyclic ligand having the sequence pyvnv (10.1021/ML100142Y )
- 1TRN: crystal structure of human trypsin 1: unexpected phosphorylation of tyrosine 151 (10.1006/JMBI.1996.0376 )
- 4C61: inhibitors of jak2 kinase domain (10.1021/JM401546N )
- 4C62: inhibitors of jak2 kinase domain (10.1021/JM401546N )
- 1UUS: structure of an activated dictyostelium stat in its dna-unbound form (10.1016/S1097-2765(04)00130-3 )
- 1UUR: structure of an activated dictyostelium stat in its dna-unbound form (10.1016/S1097-2765(04)00130-3 )
- 6GGH: human jak1 kinase domain in complex with inhibitor
- 1H9O: phosphatidylinositol 3-kinase, p85-alpha subunit: c-terminal sh2 domain complexed with a tyr751 phosphopeptide from the pdgf receptor, crystal structure at 1.79 a (10.1107/S0907444901012434 )
- 6N7D: structure of the human jak1 kinase domain with compound 54 (10.1016/J.BMCL.2019.04.008 )
- 4DWP: semet protelomerase tela covalently complexed with substrate dna (10.1371/JOURNAL.PBIO.1001472 )
- 1HCS: nmr structure of the human src sh2 domain complex (10.1021/BI00007A003 )
- 1HCT: nmr structure of the human src sh2 domain complex (10.1021/BI00007A003 )
- 6HZU: human jak1 in complex with lasw1393 (10.1021/ACS.JMEDCHEM.9B00533 )
- 6HZV: human jak3 in complex with lasw959 protein in complex with ligand (10.1021/ACS.JMEDCHEM.9B00533 )
- 2RMX: solution structure of the shp-1 c-terminal sh2 domain complexed with a tyrosine-phosphorylated peptide from nkg2a
- 2ERK: phosphorylated map kinase erk2 (10.1016/S0092-8674(00)80351-7 )
- 2IUH: crystal structure of the pi3-kinase p85 n-terminal sh2 domain in complex with c-kit phosphotyrosyl peptide (10.1038/NSB0496-364 )
- 2IUI: crystal structure of the pi3-kinase p85 n-terminal sh2 domain in complex with pdgfr phosphotyrosyl peptide (10.1038/NSB0496-364 )
- 6N7C: structure of the human jak1 kinase domain with compound 56 (10.1016/J.BMCL.2019.04.008 )
- 6N7B: structure of the human jak1 kinase domain with compound 38 (10.1016/J.BMCL.2019.04.008 )
- 3PFV: crystal structure of cbl-b tkb domain in complex with egfr py1069 peptide
- 5C26: crystal structure of syk in complex with compound 1 (10.1002/CMDC.201500333 )
- 1NH3: human topoisomerase i ara-c complex (10.1074/JBC.M212930200 )
- 3VS4: crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor 5-(4-phenoxyphenyl)-7-(tetrahydro-2h-pyran-4-yl)-7h-pyrrolo[2,3- d]pyrimidin-4-amine (10.1126/SCITRANSLMED.3004387 )
- 3VS5: crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor 7-(1-methylpiperidin-4-yl)-5-(4-phenoxyphenyl)-7h-pyrrolo[2,3- d]pyrimidin-4-amine (10.1126/SCITRANSLMED.3004387 )
- 3VS2: crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor 7-[cis-4-(4-methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7h- pyrrolo[2,3-d]pyrimidin-4-amine (10.1126/SCITRANSLMED.3004387 )
- 3VS3: crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor 7-[trans-4-(4-methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)- 7h-pyrrolo[2,3-d]pyrimidin-4-amine (10.1126/SCITRANSLMED.3004387 )
- 3VS1: crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor 1-[4-(4-amino-7-cyclopentyl-7h-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]- 3-phenylurea (10.1126/SCITRANSLMED.3004387 )
- 3PY3: crystal structure of phosphorylated p38alpha map kinase (10.1074/JBC.M110.203786 )
- 6PDJ: tyrosine-protein kinase lck bound to compound 11 (10.1021/ACSMEDCHEMLETT.9B00354 )
- 4NND: structural basis of ptpn18 fingerprint on distinct her2 tyrosine phosphorylation sites
- 3D44: crystal structure of heptp in complex with a dually phosphorylated erk2 peptide mimetic (10.1021/BI801724N )
- 3D42: crystal structure of heptp in complex with a monophosphorylated erk2 peptide (10.1021/BI801724N )
- 3VRY: crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor 4-amino-5-(4-phenoxyphenyl)-7h-pyrrolo[2,3-d]pyrimidin-7-yl- cyclopentane (10.1126/SCITRANSLMED.3004387 )
- 3VRP: crystal structure of the tyrosine kinase binding domain of cbl-c in complex with phospho-egfr peptide (10.1093/JB/MVS085 )
- 6AGX: the cocrystal structure of fgfr2 bound with compound 14 harboring 5h- pyrrolo[2,3-b]pyrazine scaffold
- 2XKK: crystal structure of moxifloxacin, dna, and a. baumannii topo iv (pare-parc fusion truncate) (10.1038/NSMB.1892 )
- 5WO4: jak1 complexed with compound 28 (10.1021/ACS.JMEDCHEM.7B01135 )
- 3MAZ: crystal structure of the human brdg1/stap-1 sh2 domain in complex with the ntal ptyr136 peptide (10.1126/SCISIGNAL.2000796 )
- 1UEF: crystal structure of dok1 ptb domain complex (10.1074/JBC.M311030200 )
- 6T6A: crystal structure of dyrk1a complexed with kufal319 (compound 11) (10.3390/MOLECULES24224090 )
- 4GVC: crystal structure of t-cell lymphoma invasion and metastasis-1 pdz in complex with phosphorylated syndecan1 peptide (10.1016/J.STR.2013.01.004 )
- 3ZNI: structure of phosphotyr363-cbl-b - ubch5b-ub - zap-70 peptide complex (10.1038/NSMB.2621 )
- 1FYR: dimer formation through domain swapping in the crystal structure of the grb2-sh2 ac-pyvnv complex (10.1021/BI0012336 )
- 1ZFP: growth factor receptor binding protein sh2 domain complexed with a phosphotyrosyl pentapeptide (10.1006/JMBI.1998.1790 )
- 5NJK: ptb domain of human numb isoform-1 (10.1083/JCB.201709092 )
- 4IWD: structure of dually phosphorylated c-met receptor kinase in complex with an mk-8033 analog (10.1021/JM301619U )
- 2OW3: glycogen synthase kinase-3 beta in complex with bis-(indole)maleimide pyridinophane inhibitor (10.1016/J.BMCL.2007.02.059 )
- 3OVE: crystal structure of the grb2 sh2 domain in complex with a pyxn- derived tripeptide (10.1021/JA2068752 )
- 3OV1: crystal structure of the grb2 sh2 domain in complex with a pyxn- derived tripeptide (10.1021/JA2068752 )
- 2PLD: nuclear magnetic resonance structure of an sh2 domain of phospholipase c-gamma1 complexed with a high affinity binding peptide (10.1016/0092-8674(94)90160-0 )
- 2PLE: nuclear magnetic resonance structure of an sh2 domain of phospholipase c-gamma1 complexed with a high affinity binding peptide (10.1016/0092-8674(94)90160-0 )
- 6NJA: structure of wt ret protein tyrosine kinase domain at 1.92a resolution. (10.1074/JBC.RA119.007682 )
- 1YGR: crystal structure of the tandem phosphatase domain of rptp cd45 (10.1084/JEM.20041890 )
- 3LPB: crystal structure of jak2 complexed with a potent 2,8-diaryl- quinoxaline inhibitor (10.1016/J.BMCL.2010.02.056 )
- 4K6Z: the jak1 kinase domain in complex with compound 37 (10.1016/J.BMCL.2013.08.082 )
- 3E64: fragment based discovery of jak-2 inhibitors (10.1016/J.BMCL.2008.08.064 )
- 6OPH: phosphorylated erk2 with gdc-0994 (10.1073/PNAS.1906824116 )
- 6OPK: phosphorylated erk2 with vertex-11e (10.1073/PNAS.1906824116 )
- 4A4C: structure of phosphotyr371-c-cbl-ubch5b-zap-70 complex (10.1038/NSMB.2231 )
- 4A4B: structure of modified phosphotyr371-c-cbl-ubch5b-zap-70 complex (10.1038/NSMB.2231 )
- 4A49: structure of phosphotyr371-c-cbl-ubch5b complex (10.1038/NSMB.2231 )
- 4P9Z: grb2 sh2 complexed with a ptyr-ac6c-asn tripeptide (10.1016/J.BMCL.2014.04.114 )
- 2L1C: shc-ptb:biphosphorylated integrin beta3 cytoplasmic tail complex (1:1) (10.1074/JBC.M110.159087 )
- 6V6L: co-structure of human glycogen synthase kinase beta with 1-(6-((2-((6- amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl) pyridin-3-yl)-4-methylpiperazin-2-one (10.1016/J.BMCL.2019.126930 )
- 3ANR: human dyrk1a/harmine complex (10.1038/NCOMMS1090 )
- 3ANQ: human dyrk1a/inhibitor complex (10.1038/NCOMMS1090 )
- 3SAY: crystal structure of human glycogen synthase kinase 3 beta (gsk3b) in complex with inhibitor 142
- 4IIR: crystal structure of amppnp-bound human prpf4b kinase domain (10.1074/JBC.M113.473348 )
- 3F88: glycogen synthase kinase 3beta inhibitor complex (10.1016/J.BMC.2009.01.019 )
- 1PKG: structure of a c-kit kinase product complex (10.1074/JBC.C300186200 )
- 1AOT: nmr structure of the fyn sh2 domain complexed with a phosphotyrosyl peptide, minimized average structure (10.1016/S0969-2126(97)00283-9 )
- 2HWL: crystal structure of thrombin in complex with fibrinogen gamma' peptide (10.1016/J.BPC.2006.08.005 )
- 2CBL: n-terminal domain of cbl in complex with its binding site on zap-70 (10.1038/18050 )
- 1G1G: crystal structure of protein tyrosine phosphatase 1b complexed with a mono-phosphorylated peptide (etdy(ptr) rkggkgll) from the insulin receptor kinase (10.1016/S1097-2765(00)00137-4 )
- 1G1F: crystal structure of protein tyrosine phosphatase 1b complexed with a tri-phosphorylated peptide (rdi(ptr) etd(ptr)(ptr)rk) from the insulin receptor kinase (10.1016/S1097-2765(00)00137-4 )
- 3KCK: a novel chemotype of kinase inhibitors (10.1016/J.BMCL.2009.11.021 )
- 4CKJ: crystal structure of ret tyrosine kinase domain bound to adenosine (10.1016/J.MOLCEL.2014.01.015 )
- 4CKI: crystal structure of oncogenic ret tyrosine kinase m918t bound to adenosine (10.1016/J.MOLCEL.2014.01.015 )
- 2MRK: fyn sh2 domain in complex with the natural inhibitory phosphotyrosine peptide (10.1016/J.STR.2016.08.016 )
- 6CZ2: structure of the ptk6 kinase domain (10.1371/JOURNAL.PONE.0198374 )
- 1LKL: human p56-lck tyrosine kinase sh2 domain in complex with the phosphotyrosyl peptide ac-ptyr-glu-glu-gly (pyeeg peptide) (10.1006/JMBI.1996.0112 )
- 1LKK: human p56-lck tyrosine kinase sh2 domain in complex with the phosphotyrosyl peptide ac-ptyr-glu-glu-ile (pyeei peptide) (10.1006/JMBI.1996.0112 )
- 3K2L: crystal structure of dual-specificity tyrosine phosphorylation regulated kinase 2 (dyrk2) (10.1016/J.STR.2013.03.012 )
- 1SEU: human dna topoisomerase i (70 kda) in complex with the indolocarbazole sa315f and covalent complex with a 22 base pair dna duplex (10.1021/JM049146P )
- 3WA4: grb2 sh2 domain/cd28-derived peptide complex (10.1371/JOURNAL.PONE.0074482 )
- 5H09: crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor (s)-ethyl2-(((1r,4s)-4-(4-amino-5-(4-phenoxyphenyl)-7h-pyrrolo[2,3- d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanoate (10.1016/J.BMC.2017.05.053 )
- 5H0H: crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor (s)-2-(((1r,4s)-4-(4-amino-5-(4-phenoxyphenyl)-7h-pyrrolo[2,3- d]pyrimidin-7-yl)cyclohexyl)amino)-n,n,4-trimethylpentanamide (10.1016/J.BMC.2017.05.053 )
- 5H0B: crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor (s)-2-(((1r,4s)-4-(4-amino-5-(4-phenoxyphenyl)-7h-pyrrolo[2,3- d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanoic acid (10.1016/J.BMC.2017.05.053 )
- 5H0G: crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor (s)-2-(((1r,4s)-4-(4-amino-5-(4-phenoxyphenyl)-7h-pyrrolo[2,3- d]pyrimidin-7-yl)cyclohexyl)amino)-n,4-dimethylpentanamide (10.1016/J.BMC.2017.05.053 )
- 6FQM: 3.06a complex of s.aureus gyrase with imidazopyrazinone t1 and dna (10.1093/NAR/GKY181 )
- 2FCI: structural basis for the requirement of two phosphotyrosines in signaling mediated by syk tyrosine kinase (10.1016/J.JMB.2005.11.095 )
- 5FM2: crystal structure of hyper-phosphorylated ret kinase domain with (proximal) juxtamembrane segment (10.1016/J.CELREP.2016.11.061 )
- 3TL0: structure of shp2 n-sh2 domain in complex with rlnpyaqlwhr peptide (10.1021/BI200439V )
- 5FM3: crystal structure of hyper-phosphorylated ret kinase domain with (proximal) juxtamembrane segment (10.1016/J.CELREP.2016.11.061 )
- 5HZ1: plant peptide hormone receptor rgfr1 in complex with rgf3
- 5NP5: abl2 sh3 ptyr116/161 (10.1074/JBC.RA118.004732 )
- 5K5N: crystal structure of gsk-3beta complexed with pf-04802367, a highly selective brain-penetrant kinase inhibitor (10.1002/ANIE.201603797 )
- 2OH4: crystal structure of vegfr2 with a benzimidazole-urea inhibitor (10.1021/JM0611051 )
- 3PLF: reverse binding mode of metrd peptide complexed with c-cbl tkb domain (10.1016/J.FEBSLET.2010.11.060 )
- 4J1R: crystal structure of gsk3b in complex with inhibitor 15r
- 3ZRM: identification of 2-(4-pyridyl)thienopyridinones as gsk- 3beta inhibitors (10.1016/J.BMCL.2011.06.050 )
- 3ZRL: identification of 2-(4-pyridyl)thienopyridinones as gsk-3beta inhibitors (10.1016/J.BMCL.2011.06.050 )
- 3ZRK: identification of 2-(4-pyridyl)thienopyridinones as gsk-3beta inhibitors (10.1016/J.BMCL.2011.06.050 )
- 5KHW: crystal structure of jak1 in complex with adp (10.1107/S2053230X16016356 )
- 2B4S: crystal structure of a complex between ptp1b and the insulin receptor tyrosine kinase (10.1016/J.STR.2005.07.019 )
- 4QUM: crystal structure of ptpn3 (ptph1) in complex with a dually phosphorylated mapk12 peptide (10.1126/SCISIGNAL.2005722 )
- 3AC5: crystal structure of triazolo pyrimidine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
- 3AC4: crystal structure of triazolo pyrimidine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
- 3AC1: crystal structure of pyrazin derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
- 3AC3: crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
- 3AC2: crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
- 3AC8: crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
- 3ACK: crystal structure of pyrrolo pyrazine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
- 3ACJ: crystal structure of imidazo pyrimidine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
- 5X7B: crystal structure of shp2_sh2-caga epiya_c peptide complex (10.1016/J.CELREP.2017.08.080 )
- 1U54: crystal structures of the phosphorylated and unphosphorylated kinase domains of the cdc42-associated tyrosine kinase ack1 bound to amp-pcp (10.1074/JBC.M406703200 )
- 3VS6: crystal structure of hck complexed with a pyrazolo-pyrimidine inhibitor tert-butyl {4-[4-amino-1-(propan-2-yl)-1h-pyrazolo[3,4- d]pyrimidin-3-yl]-2-methoxyphenyl}carbamate (10.1126/SCITRANSLMED.3004387 )
- 3VS7: crystal structure of hck complexed with a pyrazolo-pyrimidine inhibitor 1-cyclopentyl-3-(1h-pyrrolo[2,3-b]pyridin-5-yl)-1h- pyrazolo[3,4-d]pyrimidin-4-amine (10.1126/SCITRANSLMED.3004387 )
- 3VS0: crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor n-[4-(4-amino-7-cyclopentyl-7h-pyrrolo[2,3-d]pyrimidin-5-yl) phenyl]benzamide (10.1126/SCITRANSLMED.3004387 )
- 6E8M: legionella longbeachae lesh (llo2327) bound to the human dnaj-a1 ptyr381 peptide (10.1038/S41467-018-06943-2 )
- 3NNX: crystal structure of phosphorylated p38 alpha in complex with dp802 (10.1016/J.BMCL.2010.07.134 )
- 1NZV: crystal structure of src sh2 domain bound to doubly phosphorylated peptide pqpyipyvpa (10.1016/S0022-2836(03)00344-9 )
- 3F7Z: x-ray co-crystal structure of glycogen synthase kinase 3beta in complex with an inhibitor (10.1016/J.BMC.2009.01.019 )
- 4HGE: jak2 kinase (jh1 domain) in complex with compound 8 (10.1021/JM3012239 )
- 6FQS: 3.11a complex of s.aureus gyrase with imidazopyrazinone t3 and dna (10.1093/NAR/GKY181 )
- 5V60: phospho-erk2 bound to amp-pcp (10.1021/ACSMEDCHEMLETT.7B00127 )
- 4IVD: jak1 kinase (jh1 domain) in complex with compound 34 (10.1021/JM4004895 )
- 3OLL: crystal structure of phosphorylated estrogen receptor beta ligand binding domain (10.1002/CBIC.201000532 )
- 3OLR: ptpn22 in complex with consensus phospho-tyrosine peptide 1
- 6DM4: crystal structure of the sh2 domain from ravo (lpg1129) from legionella pneumophila in complex with homo sapiens shc1 phospho- tyr317 peptide
- 1K4S: human dna topoisomerase i in covalent complex with a 22 base pair dna duplex (10.1073/PNAS.242259599 )
- 1K4T: human dna topoisomerase i (70 kda) in complex with the poison topotecan and covalent complex with a 22 base pair dna duplex (10.1073/PNAS.242259599 )
- 4K77: jak1 kinase (jh1 domain) in complex with compound 6 (10.1016/J.BMCL.2013.08.082 )
- 2XA4: inhibitors of jak2 kinase domain (10.1021/JM1011319 )
- 6ROY: structure of the n-sh2 domain of the human tyrosine-protein phosphatase non-receptor type 11 in complex with the phosphorylated immune receptor tyrosine-based inhibitory motif (10.1126/SCIADV.AAY4458 )
- 6ROZ: structure of the n-sh2 domain of the human tyrosine-protein phosphatase non-receptor type 11 in complex with the phosphorylated immune receptor tyrosine-based switch motif (10.1126/SCIADV.AAY4458 )
- 4I5C: the jak1 kinase domain in complex with inhibitor (10.1016/J.BMCL.2013.04.018 )
- 5A54: dyrk1a in complex with nitro benzothiazole fragment (10.1021/ACS.JMEDCHEM.6B01086 )
- 5HLP: x-ray crystal structure of gsk3b in complex with brd3937 (10.1021/ACSCHEMBIO.6B00306 )
- 5CF6: crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl- 10-[(2s)-2,3-dihydroxypropyl]-3-methyl-7-(methylamino)-3,5,8,10- tetraazatricyclo [7.3.0.02,6]dodeca-1(9),2(6),4,7,11-pentaene-11- carboxamide (10.1021/ACSMEDCHEMLETT.5B00225 )
- 5CF4: crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl- 10-ethyl-7-[(3-methoxypropyl)amino] -3-methyl-3,5,8,10- tetraazatricyclo[7.3.0.0,6] dodeca-1(9),2(6),4,7,11-pentaene-11- carboxamide (10.1021/ACSMEDCHEMLETT.5B00225 )
- 6DF1: anti-phosphotyrosine antibody 4g10-4d5 fab complexed with phosphotyrosine peptide 05-dec-18 6df1 1 title (10.1021/JACS.8B08402 )
- 6DF2: improved anti-phosphotyrosine antibody 4g10-s5-4d5 fab complexed with phosphotyrosine peptide (10.1021/JACS.8B08402 )
- 1RQQ: crystal structure of the insulin receptor kinase in complex with the sh2 domain of aps (10.1016/S1097-2765(03)00487-8 )
- 1TCE: solution nmr structure of the shc sh2 domain complexed with a tyrosine-phosphorylated peptide from the t-cell receptor, minimized average structure (10.1073/PNAS.92.17.7784 )
- 6VHG: crystal structure of phosphorylated ret tyrosine kinase domain complexed with a pyrazolo[1,5-a]pyrimidine inhibitor (10.1021/ACSMEDCHEMLETT.0C00015 )
- 4EHZ: the jak1 kinase domain in complex with inhibitor (10.1021/JM300628C )
- 2QON: human epha3 kinase and juxtamembrane region, y596f:y602f:y742a triple mutant (10.1016/J.STR.2008.03.008 )
- 2QOB: human epha3 kinase domain, base structure (10.1016/J.STR.2008.03.008 )
- 2QOQ: human epha3 kinase and juxtamembrane region, base, amp-pnp bound structure (10.1016/J.STR.2008.03.008 )
- 2QO7: human epha3 kinase and juxtamembrane region, dephosphorylated, amp-pnp bound (10.1016/J.STR.2008.03.008 )
- 5HL0: crystal structure of c-cbl tkbd in complex with spry2 peptide (54-60, py55) refined to 2.2a resolution
- 6QHD: lysine acetylated and tyrosine phosphorylated stat3 in a complex with dna (10.1016/J.BBAGEN.2019.05.019 )
- 4IZA: structure of dually phosphorylated erk2 bound to the pea-15 death effector domain (10.1038/NCOMMS2687 )
- 3CLY: crystal structure of fgf receptor 2 (fgfr2) kinase domains trapped in trans-phosphorylation reaction (10.1073/PNAS.0807752105 )
- 5T31: exploiting an asp-glu switch in glycogen synthase kinase 3 to design paralog selective inhibitors for use in acute myeloid leukemia (10.1126/SCITRANSLMED.AAM8460 )
- 6I4X: crystal structure of socs2:elongin c:elongin b in complex with erythropoietin receptor peptide (10.1038/S41467-019-10190-4 )
- 5ZTN: the crystal structure of human dyrk2 in complex with curcumin (10.1073/PNAS.1806797115 )
- 6EIS: dyrk1a in complex with jwc-055 (10.1021/ACS.JMEDCHEM.7B01847 )
- 5KPL: glycogen synthase kinase 3 beta complexed with brd0705 (10.1126/SCITRANSLMED.AAM8460 )
- 5BS8: crystal structure of a topoisomerase ii complex (10.1073/PNAS.1525047113 )
- 2H7F: structure of variola topoisomerase covalently bound to dna (10.1016/J.MOLCEL.2006.06.015 )
- 2H7E: solution structure of the talin f3 domain in complex with a chimeric beta3 integrin-pip kinase peptide- minimized average structure (10.1016/J.CELL.2006.10.048 )
- 2H7D: solution structure of the talin f3 domain in complex with a chimeric beta3 integrin-pip kinase peptide (10.1016/J.CELL.2006.10.048 )
- 4E4M: jak2 kinase (jh1 domain) in complex with compound 30 (10.1021/JM300438J )
- 4E4L: jak1 kinase (jh1 domain) in complex with compound 30 (10.1021/JM300438J )
- 4YLK: crystal structure of dyrk1a in complex with 10-chloro-substituted 11h- indolo[3,2-c]quinolone-6-carboxylic acid inhibitor 5s (10.1021/JM501994D )
- 1A31: human reconstituted dna topoisomerase i in covalent complex with a 22 base pair dna duplex (10.1126/SCIENCE.279.5356.1504 )
- 2HMH: crystal structure of socs3 in complex with gp130(ptyr757) phosphopeptide. (10.1016/J.STR.2006.06.011 )
- 1F1W: src sh2 thref1trp mutant complexed with the phosphopeptide s(ptr)vnvqn (10.1016/S1097-2765(00)80269-5 )
- 2SRC: crystal structure of human tyrosine-protein kinase c-src, in complex with amp-pnp (10.1016/S1097-2765(00)80356-1 )
- 4JMG: crystal structure of the synthetic protein in complex with py peptide (10.1016/J.MOLCEL.2014.05.002 )
- 3KRR: crystal structure of jak2 complexed with a potent quinoxaline atp site inhibitor (10.1158/1535-7163.MCT-10-0053 )
- 1K2M: solution structure of the fha2 domain of rad53 complexed with a phosphotyrosyl peptide derived from rad9 (10.1006/JMBI.2001.5141 )
- 2GQG: x-ray crystal structure of dasatinib (bms-354825) bound to activated abl kinase domain (10.1158/0008-5472.CAN-05-4187 )
- 5WEV: identification of an imidazopyridine scaffold to generate potent and selective tyk2 inhibitors that demonstrate activity in an in vivo psoriasis model (10.1016/J.BMCL.2017.08.022 )
- 6PXC: n-terminal sh2 domain of the p120rasgap bound to a p190rhogap phosphotyrosine peptide (10.1371/JOURNAL.PONE.0226113 )
- 1QG1: growth factor receptor binding protein sh2 domain complexed with an shc-derived peptide (10.1006/JMBI.1999.2792 )
- 6BBU: crystal structure of jak1 in complex with compound 25 (10.1021/ACS.JMEDCHEM.7B01598 )
- 3ZC6: crystal structure of jak3 kinase domain in complex with an indazole substituted pyrrolopyrazine inhibitor (10.1016/J.BMCL.2013.02.012 )
- 3BYM: x-ray co-crystal structure aminobenzimidazole triazine 1 bound to lck (10.1021/JM701095M )
- 4K45: auto-inhibition and phosphorylation-induced activation of plc-gamma isozymes (10.1021/BI400433B )
- 3BU3: crystal structure of the insulin receptor kinase in complex with irs2 krlb peptide (10.1038/NSMB.1388 )
- 3BU5: crystal structure of the insulin receptor kinase in complex with irs2 krlb peptide and atp (10.1038/NSMB.1388 )
- 3BU6: crystal structure of the insulin receptor kinase in complex with irs2 krlb phosphopeptide (10.1038/NSMB.1388 )
- 3BUM: crystal structure of c-cbl-tkb domain complexed with its binding motif in sprouty2 (10.1038/EMBOJ.2008.18 )
- 3BUN: crystal structure of c-cbl-tkb domain complexed with its binding motif in sprouty4 (10.1038/EMBOJ.2008.18 )
- 3BUO: crystal structure of c-cbl-tkb domain complexed with its binding motif in egf receptor' (10.1038/EMBOJ.2008.18 )
- 3BUX: crystal structure of c-cbl-tkb domain complexed with its binding motif in c-met (10.1038/EMBOJ.2008.18 )
- 3BUW: crystal structure of c-cbl-tkb domain complexed with its binding motif in syk (10.1038/EMBOJ.2008.18 )
- 4CH8: high-salt crystal structure of a thrombin-gpibalpha peptide complex (10.1016/J.JMB.2013.11.027 )
- 4CH2: low-salt crystal structure of a thrombin-gpibalpha peptide complex (10.1016/J.JMB.2013.11.027 )
- 5NJJ: ptb domain of human numb isoform-1 (10.1083/JCB.201709092 )
- 5X94: crystal structure of shp2_sh2-caga epiya_d peptide complex (10.1016/J.CELREP.2017.08.080 )
- 4ZIM: crystal structure of janus kinase 2 in complex with a 9h-carbazole-1- carboxamide inhibitor (10.1016/J.BMCL.2015.04.101 )
- 5USY: jak2 jh1 in complex with jnj-7706621 (10.1021/ACSMEDCHEMLETT.7B00153 )
- 4ZRT: ptp1bc215s bound to nephrin peptide substrate (10.1021/BI401223R )
- 4YTF: discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune diseases (10.1021/ACS.JMEDCHEM.5B00301 )
- 4YTC: discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune disease (10.1021/ACS.JMEDCHEM.5B00301 )
- 3CI5: complex of phosphorylated dictyostelium discoideum actin with gelsolin (10.1073/PNAS.0805852105 )
- 2J17: ptyr bound form of sdp-1 (10.1038/NATURE05804 )
- 1FU5: nmr structure of the n-sh2 domain of the p85 subunit of pi3- kinase complexed to a doubly phosphorylated peptide derived from polyomavirus middle t antigen (10.1021/BI001474D )
- 6B67: human pp2calpha (ppm1a) complexed with cyclic peptide c(mpsipyva) (10.1074/JBC.RA117.001213 )
- 1RRJ: structural mechanisms of camptothecin resistance by mutations in human topoisomerase i (10.1016/J.JMB.2004.03.077 )
- 5A3X: dyrk1a in complex with hydroxy benzothiazole fragment (10.1021/ACS.JMEDCHEM.6B01086 )
- 6R5G: c-sh2 domain of shp-2 in complex with phospho-itsm of pd-1 (10.1126/SCIADV.AAY4458 )
- 6OHP: structure of compound 1 (halopemide) bound human phospholipase d2 catalytic domain (10.1038/S41589-019-0458-4 )
- 2NMB: dnumb ptb domain complexed with a phosphotyrosine peptide, nmr, ensemble of structures. (10.1038/4185 )
- 1J4X: human vh1-related dual-specificity phosphatase c124s mutant- peptide complex (10.1021/BI015799L )
- 1J4K: solution structure of the fha2 domain of rad53 complexed with a phosphotyrosyl peptide derived from rad9 (10.1006/JMBI.2001.5141 )
- 2MC1: solution structure of the vav1 sh2 domain complexed with a syk-derived singly phosphorylated peptide (10.1002/BIP.22371 )
- 3U3Z: structure of human microcephalin (mcph1) tandem brct domains in complex with an h2a.x peptide phosphorylated at ser139 and tyr142 (10.1073/PNAS.1212366109 )
- 3DQW: c-src kinase domain thr338ile mutant in complex with atpgs (10.1038/NSMB.1486 )
- 1OO4: p395s mutant of the p85 regulatory subunit of the n- terminal src homology 2 domain of pi3-kinase complexed to a peptide derived from pdgfr (10.1021/BI034353X )
- 1CSY: syk tyrosine kinase c-terminal sh2 domain complexed with a phosphopeptidefrom the gamma chain of the high affinity immunoglobin g receptor, nmr (10.1016/S0969-2126(01)00242-8 )
- 1CSZ: syk tyrosine kinase c-terminal sh2 domain complexed with a phosphopeptidefrom the gamma chain of the high affinity immunoglobin g receptor, nmr (10.1016/S0969-2126(01)00242-8 )
- 6N79: structure of the human jak1 kinase domain with compound 20 (10.1016/J.BMCL.2019.04.008 )
- 6N78: structure of the human jak1 kinase domain with compound 21 (10.1016/J.BMCL.2019.04.008 )
- 6N77: structure of the human jak1 kinase domain with compound 15 (10.1016/J.BMCL.2019.04.008 )
- 1MW4: solution structure of the human grb7-sh2 domain in complex with a 10 amino acid peptide py1139 (10.1023/A:1025498409113 )
- 4AZF: human dyrk2 in complex with leucettine l41 (10.1021/JM301034U )
- 4AZE: human dyrk1a in complex with leucettine l41 (10.1021/JM301034U )
- 1K3A: structure of the insulin-like growth factor 1 receptor kinase (10.1038/NSB721 )
- 1NZL: crystal structure of src sh2 domain bound to doubly phosphorylated peptide pqpyepyipi (10.1016/S0022-2836(03)00344-9 )
- 5W86: crystal structure of jak3 kinase domain with a 4,6-diaminonicotinamide inhibitor (compound number 7) (10.1016/J.BMCL.2017.09.029 )
- 1GAG: crystal structure of the insulin receptor kinase in complex with a bisubstrate inhibitor (10.1038/83028 )
- 5CF8: crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl- 10-ethyl-7-[(3-methoxypropyl)amino] -3-methyl-3,5,8,10- tetraazatricyclo[7.3.0.0,6] dodeca-1(9),2(6),4,7,11-pentaene-11- carboxamide (10.1021/ACSMEDCHEMLETT.5B00226 )
- 1A07: c-src (sh2 domain) complexed with ace-malonyl tyr-glu-(n,n-dipentyl amine) (10.1021/BI970019N )
- 5HZ0: plant peptide hormone receptor rgfr1 in complex with rgf2
- 5HZ3: plant peptide hormone receptor rgfr1 in complex with rgfr5
- 1JU5: ternary complex of an crk sh2 domain, crk-derived phophopeptide, and abl sh3 domain by nmr spectroscopy (10.1073/PNAS.212518799 )
- 3DA9: crystal structure of thrombin in complex with inhibitor (10.1021/JM8011849 )
- 5CDM: 2.5a structure of qpt-1 with s.aureus dna gyrase and dna (10.1038/NCOMMS10048 )
- 5CDO: 3.15a structure of qpt-1 with s.aureus dna gyrase and dna (10.1038/NCOMMS10048 )
- 6B8J: co-structure of human glycogen synthase kinase beta with a selective (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino) ethyl]amine inhibitor (10.1021/ACS.JMEDCHEM.7B00922 )
- 5AEP: novel pyrrole carboxamide inhibitors of jak2 as potential treatment of myeloproliferative disorders (10.1016/J.BMC.2015.03.059 )
- 1SHD: peptide inhibitors of src sh3-sh2-phosphoprotein interactions
- 1SHA: crystal structure of the phosphotyrosine recognition domain sh2 of v-src complexed with tyrosine-phosphorylated peptides (10.1038/358646A0 )
- 1SHC: shc ptb domain complexed with a trka receptor phosphopeptide, nmr, minimized average structure (10.1038/378584A0 )
- 4YJR: syk kinase domain in complex with inhibitor gtc000225 (10.1016/J.BMCL.2011.07.082 )
- 4YJQ: syk kinase domain in complex with inhibitor gtc000224 (10.1016/J.BMCL.2011.07.082 )
- 4YJV: the kinase domain of human spleen tyrosine (syk) in complex with gtc000250
- 4YJU: the kinase domain of human spleen tyrosine (syk) in complex with gtc000249 (10.1016/J.BMCL.2011.07.082 )
- 4YJT: the kinase domain of human spleen tyrosine (syk) in complex with gtc000233 (10.1016/J.BMCL.2011.07.082 )
- 1FPR: crystal structure of the complex formed between the catalytic domain of shp-1 and an in vitro peptide substrate py469 derived from shps-1. (10.1074/JBC.275.6.4066 )
- 2DVJ: phosphorylated crk-ii (10.1038/NSMB1241 )
- 3FUP: crystal structures of jak1 and jak2 inhibitor complexes (10.1016/J.JMB.2009.01.041 )
- 5A4L: dyrk1a in complex with fluoro benzothiazole fragment (10.1021/ACS.JMEDCHEM.6B01086 )
- 5A4E: dyrk1a in complex with methoxy benzothiazole fragment (10.1021/ACS.JMEDCHEM.6B01086 )
- 5A4T: dyrk1a in complex with nitrile benzothiazole fragment (10.1021/ACS.JMEDCHEM.6B01086 )
- 1QPD: structural analysis of the lymphocyte-specific kinase lck in complex with non-selective and src family selective kinase inhibitors (10.1016/S0969-2126(99)80086-0 )
- 1QPE: structural analysis of the lymphocyte-specific kinase lck in complex with non-selective and src family selective kinase inhibitors (10.1016/S0969-2126(99)80086-0 )
- 1QPC: structural analysis of the lymphocyte-specific kinase lck in complex with non-selective and src family selective kinase inhibitors (10.1016/S0969-2126(99)80086-0 )
- 1QPJ: crystal structure of the lymphocyte-specific kinase lck in complex with staurosporine. (10.1016/S0969-2126(99)80086-0 )
- 5A4Q: dyrk1a in complex with chloro benzothiazole fragment (10.1021/ACS.JMEDCHEM.6B01086 )
- 3ZMM: inhibitors of jak2 kinase domain (10.1016/J.BMCL.2013.02.111 )
- 1GNG: glycogen synthase kinase-3 beta (gsk3) complex with frattide peptide (10.1016/S0969-2126(01)00679-7 )
- 5E1E: human jak1 kinase in complex with compound 30 at 2.30 angstroms resolution (10.1016/J.BMCL.2015.11.031 )
- 2CIA: human nck2 sh2-domain in complex with a decaphosphopeptide from translocated intimin receptor (tir) of epec (10.1074/JBC.M512917200 )
- 4LUE: crystal structure of hck in complex with 7-[trans-4-(4- methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7h-pyrrolo[2,3- d]pyrimidin-4-amine (resulting from displacement of skf86002) (10.1107/S1399004713028654 )
- 4LUD: crystal structure of hck in complex with the fluorescent compound skf86002 (10.1107/S1399004713028654 )
- 2CI9: nck1 sh2-domain in complex with a dodecaphosphopeptide from epec protein tir (10.1074/JBC.M512917200 )
- 2MFQ: nmr solution structures of frs2a ptb domain with neurotrophin receptor trkb (10.1002/PROT.24523 )
- 4V0G: jak3 in complex with a covalent egfr inhibitor
- 3GQI: crystal structure of activated receptor tyrosine kinase in complex with substrates (10.1016/J.CELL.2009.05.028 )
- 4K11: the structure of 1na in complex with src t338g
- 1I3Z: murine eat2 sh2 domain in complex with slam phosphopeptide (10.1093/EMBOJ/20.21.5840 )
- 6HM7: crystal structure of spleen tyrosine kinase (syk) in complex with a 2- (phenoxymethyl)pyridine inhibitor (10.1016/J.BMCL.2018.09.022 )
- 6HM6: crystal structure of spleen tyrosine kinase (syk) in complex with a 2- (pyridinyloxymethyl)pyridine inhibitor (10.1016/J.BMCL.2018.09.022 )
- 3KXZ: the complex crystal structure of lck with a probe molecule w259 (10.1021/JM901525B )
- 4R3R: crystal structures of egfr in complex with mig6 (10.1038/NSMB.3074 )
- 3JY9: janus kinase 2 inhibitors (10.1021/JM901383U )
- 4E4N: jak1 kinase (jh1 domain) in complex with compound 49 (10.1021/JM300438J )
- 6S17: crystal structure of dyrk1a with small molecule inhibitor
- 6S14: crystal structure of dyrk1a with small molecule inhibitor
- 6S1J: crystal structure of dyrk1a with small molecule inhibitor
- 4FK6: jak1 kinase (jh1 domain) in complex with compound 72 (10.1016/J.BMCL.2012.10.008 )
- 2OQ1: tandem sh2 domains of zap-70 with 19-mer zeta1 peptide (10.1038/377032A0 )
- 5CDW: crystal structure analysis of a mutant grb2 sh2 domain (w121g) with a pyvnv peptide (10.1002/PRO.2856 )
- 5CDQ: 2.95a structure of moxifloxacin with s.aureus dna gyrase and dna (10.1038/NCOMMS10048 )
- 1BF5: tyrosine phosphorylated stat-1/dna complex (10.1016/S0092-8674(00)81443-9 )
- 1XXP: yersinia yoph (residues 163-468) c403s binds phosphotyrosyl peptide at two sites (10.1111/J.1365-2958.2005.04477.X )
- 2ZYB: crystal structure of phenylimidazo pyrazin 2 bound to the kinase domain of human lck, (auto-phosphorylated on tyr394) (10.1016/J.BMC.2008.10.041 )
- 4U1P: human fyn-sh2 domain in complex with a synthetic high-affinity phospho-peptide
- 3KUL: kinase domain of human ephrin type-a receptor 8 (epha8)
- 5NZZ: crystal structure of phosphorylated p38amapk in complex with tab1 (10.1172/JCI.INSIGHT.121144 )
- 5BTF: crystal structure of a topoisomerase ii complex (10.1073/PNAS.1525047113 )
- 5KHX: crystal structure of jak1 in complex with pf-4950736 (10.1107/S2053230X16016356 )
- 2RSY: solution structure of the sh2 domain of csk in complex with a phosphopeptide from cbp (10.1074/JBC.M112.439075 )
- 6AE3: crystal structure of gsk3beta complexed with morin (10.1016/J.BBRC.2018.08.182 )
- 1PIC: phosphatidylinositol 3-kinase, p85-alpha subunit: c- terminal sh2 domain complexed with a tyr751 phosphopeptide from the pdgf receptor, nmr, minimized mean structure
- 5TQ4: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
- 5TQ6: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
- 5TQ7: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
- 5TQ1: phospholipase c gamma-1 c-terminal sh2 domain bound to a phosphopeptide derived from the insulin receptor (10.1021/ACS.BIOCHEM.7B00023 )
- 1KC2: structure of the triple (lys(beta)d3ala, asp(beta)c8ala, aspcd2ala) mutant of the src sh2 domain bound to the pqpyeeipi peptide (10.1006/JMBI.2001.5362 )
- 2IVT: crystal structure of phosphorylated ret tyrosine kinase domain (10.1074/JBC.M605604200 )
- 2IVV: crystal structure of phosphorylated ret tyrosine kinase domain complexed with the inhibitor pp1 (10.1074/JBC.M605604200 )
- 4MYG: mapk13, active form (10.1107/S1399004715001212 )
- 4E6Q: jak2 kinase (jh1 domain) triple mutant in complex with compound 12 (10.1021/JM300438J )
- 2DXP: crystal structure of the complex of the archaeal sulfolobus ptp-fold phosphatase with phosphopeptides a-(p)y-r (10.1002/PROT.21262 )
- 4P7E: triazolopyridine compounds as selective jak1 inhibitors: from hit identification to glpg0634 (10.1021/JM501262Q )
- 1YWN: vegfr2 in complex with a novel 4-amino-furo[2,3-d]pyrimidine (10.1016/J.BMCL.2005.03.034 )
- 2MMK: y41 and t47 phosphorylation of the mengovirus leader protein: nmr studies of the phosphorylation of the mengovirus leader protein reveal stabilization of intermolecular domain interactions (10.1073/PNAS.1411098111 )
- 1A81: crystal structure of the tandem sh2 domain of the syk kinase bound to a dually tyrosine-phosphorylated itam (10.1006/JMBI.1998.1964 )
- 3RVG: crystals structure of jak2 with a 1-amino-5h-pyrido[4,3-b]indol-4- carboxamide inhibitor (10.1021/JM200909U )
- 1SPS: binding of a high affinity phosphotyrosyl peptide to the src sh2 domain: crystal structures of the complexed and peptide-free forms (10.1016/0092-8674(93)90405-F )
- 2IVU: crystal structure of phosphorylated ret tyrosine kinase domain complexed with the inhibitor zd6474 (10.1074/JBC.M605604200 )
- 5CDN: 2.8a structure of etoposide with s.aureus dna gyrase and dna (10.1038/NCOMMS10048 )
- 1SC7: human dna topoisomerase i (70 kda) in complex with the indenoisoquinoline mj-ii-38 and covalent complex with a 22 base pair dna duplex (10.1021/JM049146P )
- 2J0L: crystal structure of a the active conformation of the kinase domain of focal adhesion kinase with a phosphorylated activation loop. (10.1016/J.CELL.2007.05.041 )
- 4F5B: triple mutant src sh2 domain bound to phosphotyrosine (10.1126/SCISIGNAL.2003021 )
- 5GJH: gads sh2 domain/cd28-derived peptide complex (10.1074/JBC.M116.755173 )
- 5GJI: pi3k p85 n-terminal sh2 domain/cd28-derived peptide complex (10.1074/JBC.M116.755173 )
- 5LMA: human spleen tyrosine kinase kinase domain in complex with azanaphthyridine inhibitor (10.1016/J.BMCL.2016.08.070 )
- 5LMB: human spleen tyrosine kinase kinase domain in complex with azanaphthyridine inhibitor (10.1016/J.BMCL.2016.08.070 )
- 2G35: nmr structure of talin-ptb in complex with pipki (10.1016/J.JMB.2006.02.048 )
- 6DRW: jak2 jh1 in complex with jnj-7706621 (crystal form 2)
- 1PTT: crystal structure of protein tyrosine phosphatase 1b complexed with phosphotyrosine-containing tetra-peptide (ac-depyl-nh2)
- 1PTY: crystal structure of protein tyrosine phosphatase 1b complexed with two phosphotyrosine molecules (10.1073/PNAS.94.25.13420 )
- 4GFM: jak2 kinase (jh1 domain) with 2,6-dichloro-n-(2-oxo-2,5- dihydropyridin-4-yl)benzamide (10.1016/J.EJMECH.2013.03.070 )
- 4GFV: ptpn18 in complex with her2-py1196 phosphor-peptides
- 1D4W: crystal structure of the xlp protein sap in complex with slam phosphopeptide (10.1016/S1097-2765(00)80206-3 )
- 6OI4: rpn13 (19-132)-rpn2 (940-952) py950-ub complex (10.1074/JBC.AC119.008881 )
- 6PJJ: human prpf4b bound to benzothiophene inhibitor 224
- 2PTK: chicken src tyrosine kinase (10.1006/JMBI.1997.1426 )
- 3Q32: structure of janus kinase 2 with a pyrrolotriazine inhibitor (10.1016/J.BMCL.2011.01.022 )
- 1YGU: crystal structure of the tandem phosphatase domains of rptp cd45 with a ptyr peptide (10.1084/JEM.20041890 )
- 5LXD: crystal structure of dyrk2 in complex with eht 1610 (compound 2) (10.1021/ACS.JMEDCHEM.6B01083 )
- 5LXC: crystal structure of dyrk2 in complex with eht 5372 (compound 1) (10.1021/ACS.JMEDCHEM.6B01083 )
- 1YRK: the c2 domain of pkc
is a new phospho-tyrosine binding domain (10.1016/J.CELL.2005.02.019 ) - 5AXI: crystal structure of cbl-b tkb domain in complex with cblin (10.1016/J.ABB.2016.02.014 )
- 3E62: fragment based discovery of jak-2 inhibitors (10.1016/J.BMCL.2008.08.064 )
- 3E63: fragment based discovery of jak-2 inhibitors (10.1016/J.BMCL.2008.08.064 )
- 1TZE: signal transduction adaptor growth factor, grb2 sh2 domain complexed with phosphotyrosyl heptapeptide lys-pro-phe-ptyr-val-asn-val-nh2 (kfppyvnc-nh2) (10.1038/NSB0796-586 )
- 1CM8: phosphorylated map kinase p38-gamma (10.1016/S0969-2126(99)80173-7 )
- 4IFC: crystal structure of adp-bound human prpf4b kinase domain (10.1074/JBC.M113.473348 )
- 5V62: phospho-erk2 bound to bivalent inhibitor sbp3 (10.1021/ACSMEDCHEMLETT.7B00127 )
- 5V61: phospho-erk2 bound to bivalent inhibitor sbp2 (10.1021/ACSMEDCHEMLETT.7B00127 )
- 3F5P: complex structure of insulin-like growth factor receptor and 3- cyanoquinoline inhibitor (10.1016/J.BMCL.2008.11.037 )
- 4GMY: jak2 kinase (jh1 domain) in complex with 2,6-dichloro-n-{2- [(cyclopropylcarbonyl)amino]pyridin-4-yl}benzamide (10.1016/J.EJMECH.2013.03.070 )
- 4P9V: grb2 sh2 complexed with a ptyr-ac6cn-asn tripeptide (10.1016/J.BMCL.2014.04.114 )
- 6QU2: crystal structure of dyrk1a complexed with fc162 inhibitor
- 1AYA: crystal structures of peptide complexes of the amino- terminal sh2 domain of the syp tyrosine phosphatase (10.1016/S0969-2126(00)00044-7 )
- 1AYC: crystal structures of peptide complexes of the amino- terminal sh2 domain of the syp tyrosine phosphatase (10.1016/S0969-2126(00)00044-7 )
- 1AYB: crystal structures of peptide complexes of the amino- terminal sh2 domain of the syp tyrosine phosphatase (10.1016/S0969-2126(00)00044-7 )
- 4RHG: crystal structure of ptpn3 (ptph1) d811e, c842s mutant in complex with eps15 ptyr849 peptide (10.1016/J.STR.2015.01.017 )
- 4RH5: crystal structure of ptpn3 (ptph1) in complex with eps15 ptyr849 peptide (10.1016/J.STR.2015.01.017 )
- 4RH9: crystal structure of ptpn3 (ptph1) h812f, m883g mutant in complex with eps15 ptyr849 peptide (10.1016/J.STR.2015.01.017 )
- 1QCF: crystal structure of hck in complex with a src family-selective tyrosine kinase inhibitor (10.1016/S1097-2765(00)80357-3 )
- 5OY4: gsk3beta complex with n-(6-(3,4-dihydroxyphenyl)-1h-pyrazolo[3,4- b]pyridin-3-yl)acetamide (10.1021/ACSMEDCHEMLETT.7B00296 )
- 6S1B: crystal structure of dyrk1a with small molecule inhibitor
- 6S1I: crystal structure of dyrk1a with small molecule inhibitor
- 3LXP: structural and thermodynamic characterization of the tyk2 and jak3 kinase domains in complex with cp-690550 and cmp-6 (10.1016/J.JMB.2010.05.020 )
- 3LXN: structural and thermodynamic characterization of the tyk2 and jak3 kinase domains in complex with cp-690550 and cmp-6 (10.1016/J.JMB.2010.05.020 )
- 3BYO: x-ray co-crystal structure of 2-amino-6-phenylpyrimido[5', 4':5,6]pyrimido[1,2-a]benzimidazol-5(6h)-one 25 bound to lck (10.1021/JM701095M )
- 2BBU: solution structure of mouse socs3 in complex with a phosphopeptide from the gp130 receptor (10.1016/J.MOLCEL.2006.03.024 )
- 6GN1: crystal structure of glycogen synthase kinase-3 beta (gsk3b) in complex with pik-75 (10.1002/ANIE.201804917 )
- 4EI4: jak1 kinase (jh1 domain) in complex with compound 20 (10.1021/JM300628C )
- 2C0I: src family kinase hck with bound inhibitor a-420983 (10.1016/J.BMCL.2005.09.039 )
- 2C0O: src family kinase hck with bound inhibitor a-770041 (10.1016/J.BMCL.2005.09.039 )
- 2C0T: src family kinase hck with bound inhibitor a-641359 (10.1016/J.BMCL.2005.09.039 )
- 3S3H: crystal structure of the catalytic domain of ptp10d from drosophila melanogaster with a phosphopeptide substrate gp4 (10.1021/BI201092Q )
- 2W1I: structure determination of aurora kinase in complex with inhibitor (10.1021/JM800984V )
- 6S11: crystal structure of dyrk1a with small molecule inhibitor
- 1R1S: structural basis for differential recognition of tyrosine phosphorylated sites in the linker for activation of t cells (lat) by the adaptor protein gads (10.1038/SJ.EMBOJ.7600168 )
- 1R1P: structural basis for differential recognition of tyrosine phosphorylated sites in the linker for activation of t cells (lat) by the adaptor protein gads (10.1038/SJ.EMBOJ.7600168 )
- 1R1Q: structural basis for differential recognition of tyrosine phosphorylated sites in the linker for activation of t cells (lat) by the adaptor protein gads (10.1038/SJ.EMBOJ.7600168 )
- 1SHB: crystal structure of the phosphotyrosine recognition domain sh2 of v-src complexed with tyrosine-phosphorylated peptides (10.1038/358646A0 )
- 2WO6: human dual-specificity tyrosine-phosphorylation-regulated kinase 1a in complex with a consensus substrate peptide (10.1016/J.STR.2013.03.012 )
- 3DK6: crystal structure of mutant abl kinase domain in complex with small molecule fragment
- 3DK7: crystal structure of mutant abl kinase domain in complex with small molecule fragment
- 4F09: discovery and optimization of c-2 methyl imidazo-pyrrolopyridines as potent and orally bioavailable jak1 inhibitors with selectivity over jak2 (10.1021/JM300628C )
- 1O9U: glycogen synthase kinase 3 beta complexed with axin peptide (10.1093/EMBOJ/CDG068 )
- 3OP0: crystal structure of cbl-c (cbl-3) tkb domain in complex with egfr py1069 peptide
- 5BTL: crystal structure of a topoisomerase ii complex (10.1073/PNAS.1525047113 )
- 5BTN: crystal structure of a topoisomerase ii complex (10.1073/PNAS.1525047113 )
- 5BTI: crystal structure of a topoisomerase ii complex (10.1073/PNAS.1525047113 )
- 5BTD: crystal structure of a topoisomerase ii complex (10.1073/PNAS.1525047113 )
- 5BTG: crystal structure of a topoisomerase ii complex (10.1073/PNAS.1525047113 )
- 5BTA: crystal structure of a topoisomerase ii complex (10.1073/PNAS.1525047113 )
- 5BTC: crystal structure of a topoisomerase ii complex (10.1073/PNAS.1525047113 )
- 2LCT: solution structure of the vav1 sh2 domain complexed with a syk-derived doubly phosphorylated peptide (10.1128/MCB.05043-11 )
- 2CJZ: crystal structure of the c472s mutant of human protein tyrosine phosphatase ptpn5 (step, striatum enriched phosphatase) in complex with phosphotyrosine (10.1016/J.CELL.2008.11.038 )
- 2CJM: mechanism of cdk inhibition by active site phosphorylation: cdk2 y15p t160p in complex with cyclin a structure (10.1074/JBC.M609151200 )
- 2B7A: the structural basis of janus kinase 2 inhibition by a potent and specific pan-janus kinase inhibitor (10.1182/BLOOD-2005-06-2413 )
- 6AAH: crystal structure of jak1 in complex with peficitinib (10.1016/J.BMC.2018.08.005 )
- 6AAJ: crystal structure of jak2 in complex with peficitinib (10.1016/J.BMC.2018.08.005 )
- 6AAK: crystal structure of jak3 in complex with peficitinib (10.1016/J.BMC.2018.08.005 )
- 4EY0: structure of tandem sh2 domains from plcgamma1 (10.1016/J.STR.2012.09.005 )
- 1JYR: xray structure of grb2 sh2 domain complexed with a phosphorylated peptide (10.1006/JMBI.2001.5299 )
- 1JYQ: xray structure of grb2 sh2 domain complexed with a highly affine phospho peptide (10.1006/JMBI.2001.5299 )
- 4IAN: crystal structure of apo human prpf4b kinase domain (10.1074/JBC.M113.473348 )
- 3SRV: crystal structure of spleen tyrosine kinase (syk) in complex with a diaminopyrimidine carboxamide inhibitor (10.1016/J.BMCL.2011.07.082 )
- 4IJP: crystal structure of human prpf4b kinase domain in complex with 4-{5- [(2-chloro-pyridin-4-ylmethyl)-carbamoyl]-thiophen-2-yl}- benzo[b]thiophene-2-carboxylic acid amine (10.1074/JBC.M113.473348 )
- 1M0V: nmr structure of the type iii secretory domain of yersinia yoph complexed with the skap-hom phospho-peptide n-acetyl- depyddpf-nh2 (10.1021/BI026333L )
- 2DQ7: crystal structure of fyn kinase domain complexed with staurosporine (10.1016/J.BBRC.2006.05.212 )
- 5HLN: x-ray crystal structure of gsk3b in complex with chir99021 (10.1021/ACSCHEMBIO.6B00306 )
- 5CF5: crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl- 7-[(dimethyl-1,3-thiazol-2-yl)amino]-10-ethyl-3-methyl-3,5,8,10- tetraazatricyclo[7.3.0.02,6] dodeca-1(9),2(6),4,7,11-pentaene-11- carboxamide (10.1021/ACSMEDCHEMLETT.5B00225 )
- 3EYG: crystal structures of jak1 and jak2 inhibitor complexes 10-feb-09 3eyg 1 title (10.1016/J.JMB.2009.01.041 )
- 3EYH: crystal structures of jak1 and jak2 inhibitor complexes 10-feb-09 3eyh 1 title (10.1016/J.JMB.2009.01.041 )
- 3VRR: crystal structure of the tyrosine kinase binding domain of cbl-c (pl mutant) in complex with phospho-egfr peptide (10.1093/JB/MVS085 )
- 4AFJ: 5-aryl-4-carboxamide-1,3-oxazoles: potent and selective gsk-3 inhibitors (10.1016/J.BMCL.2012.01.034 )
- 1PTV: crystal structure of protein tyrosine phosphatase 1b complexed with phosphotyrosine
- 5AIK: human dyrk1a in complex with ldn-211898
- 4Z16: crystal structure of the jak3 kinase domain covalently bound to n-(3- (((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino) pyrimidin-4-yl)amino)methyl)phenyl)acrylamide (10.1021/ACS.JMEDCHEM.5B00710 )
- 1BG1: transcription factor stat3b/dna complex (10.1038/28101 )
- 4JIA: jak2 kinase (jh1 domain) in complex with compound 9 (10.1016/J.BMCL.2013.06.008 )
- 4D0W: pyrrole-3-carboxamides as potent and selective jak2 inhibitors (10.1016/J.BMC.2014.06.025 )
- 1LCJ: sh2 (src homology-2) domain of human p56-lck tyrosine kinase complexed with the 11 residue phosphotyrosyl peptide epqpyeeipiyl (10.1038/362087A0 )
- 1LCK: sh3-sh2 domain fragment of human p56-lck tyrosine kinase complexed with the 10 residue synthetic phosphotyrosyl peptide tegqpyqpqpa (10.1038/368764A0 )
- 4JFX: structure of phosphotyrosine (ptyr) scaffold bound to ptyr peptide 02-oct-13 4jfx 1 title (10.1038/NBT.2672 )
- 2ETZ: the nmr minimized average structure of the itk sh2 domain bound to a phosphopeptide (10.1016/J.JMB.2005.12.073 )
- 4AQC: triazolopyridine-based inhibitor of janus kinase 2 (10.1021/JM300248Q )
- 3FXX: human epha3 kinase and juxtamembrane region bound to substrate kqwdnye[ptyr]iw (10.1111/J.1742-4658.2009.07147.X )
- 3LCK: the kinase domain of human lymphocyte kinase (lck), activated form (auto-phosphorylated on tyr394) (10.1038/384484A0 )
- 5CZH: egfr l858r mutant in complex with an optimal peptide substrate (10.1038/NSMB.3117 )
- 5CZI: egfr l858r mutant in complex with a shc peptide substrate (10.1038/NSMB.3117 )
- 4EWH: co-crystal structure of ack1 with inhibitor (10.1016/J.BMCL.2012.08.020 )
- 6A1F: crystal structure of human dyrk1a in complex with compound 14 (10.1016/J.BMCL.2018.09.010 )
- 4E10: protelomerase tela y201a covalently complexed with substrate dna (10.1371/JOURNAL.PBIO.1001472 )
- 1YVJ: crystal structure of the jak3 kinase domain in complex with a staurosporine analogue (10.1182/BLOOD-2005-02-0707 )
- 1TL8: human dna topoisomerase i (70 kda) in complex with the indenoisoquinoline ai-iii-52 and covalent complex with a 22 base pair dna duplex (10.1021/JM050076B )
- 2LNW: identification and structural basis for a novel interaction between vav2 and arap3 (10.1016/J.JSB.2012.06.011 )
- 4JI9: jak2 kinase (jh1 domain) in complex with tg101209 (10.1016/J.BMCL.2013.06.008 )
- 3MXC: structures of grb2-sh2 domain and aicd peptide complexes reveal a conformational switch and their functional implications. (10.1016/J.JMB.2011.09.046 )
- 3MXY: structures of grb2-sh2 domain and aicd peptide complexes reveal a conformational switch and their functional implications. (10.1016/J.JMB.2011.09.046 )
- 4D1S: pyrrole-3-carboxamides as potent and selective jak2 inhibitors (10.1016/J.BMC.2014.06.025 )
- 1AOU: nmr structure of the fyn sh2 domain complexed with a phosphotyrosyl peptide, 22 structures (10.1016/S0969-2126(97)00283-9 )
- 5HYX: plant peptide hormone receptor rgfr1 in complex with rgf1 (10.1038/CR.2016.62 )
- 1X27: crystal structure of lck sh2-sh3 with sh2 binding site of p130cas (10.1002/JMR.755 )
- 2H8H: src kinase in complex with a quinazoline inhibitor (10.1021/JM060434Q )
- 3OB2: crystal structure of c-cbl tkb domain in complex with double phosphorylated egfr peptide (10.1371/JOURNAL.PONE.0012819 )
- 4E0P: protelomerase tela covalently complexed with substrate dna (10.1371/JOURNAL.PBIO.1001472 )
- 4E0Y: protelomerase tela covalently complexed with mutated substrate dna (10.1371/JOURNAL.PBIO.1001472 )
- 4E0Z: protelomerase tela r205a covalently complexed with substrate dna (10.1371/JOURNAL.PBIO.1001472 )
- 2VIF: crystal structure of socs6 sh2 domain in complex with a c-kit phosphopeptide (10.1074/JBC.M110.173526 )
- 5DF6: crystal structure of ptpn11 tandem sh2 domains in complex with a txnip peptide (10.1042/BJ20150830 )
- 5EG3: crystal structure of the activated fgf receptor 2 (fgfr2) kinase domain in complex with the csh2 domain of phospholipase c gamma (plcgamma) 28-dec-16 5eg3 1 title (10.1016/J.MOLCEL.2015.11.010 )
- 3ML4: crystal structure of a complex between dok7 ph-ptb and the musk juxtamembrane region (10.1016/J.MOLCEL.2010.06.007 )
- 6EJ4: dyrk1a in complex with xmd7-112 (10.1021/ACS.JMEDCHEM.7B01847 )
- 4XZ1: zap-70-tsh2:compound-b adduct (10.1042/BJ20140793 )
- 4R3P: crystal structures of egfr in complex with mig6 (10.1038/NSMB.3074 )
- 4YTI: discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune disease (10.1021/ACS.JMEDCHEM.5B00301 )
- 4YTH: discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune diseases (10.1021/ACS.JMEDCHEM.5B00301 )
- 6DBM: tyk2 with compound 23 (10.1021/ACS.JMEDCHEM.8B00917 )
- 4GFH: topoisomerase ii-dna-amppnp complex (10.1038/NSMB.2388 )
- 6ITV: crystal structure of activated c-kit in complex with compound
- 4GFU: ptpn18 in complex with her2-py1248 phosphor-peptides
- 6EIP: dyrk1a in complex with xmd8-62e (10.1021/ACS.JMEDCHEM.7B01847 )
- 6EIQ: dyrk1a in complex with xmd14-124 (10.1021/ACS.JMEDCHEM.7B01847 )
- 6EIR: dyrk1a in complex with xmd15-27-2 (10.1021/ACS.JMEDCHEM.7B01847 )
- 6EIV: dyrk1a in complex with jwd-065 (10.1021/ACS.JMEDCHEM.7B01847 )
- 6EIF: dyrk1a in complex with xmd7-117 (10.1021/ACS.JMEDCHEM.7B01847 )
- 6EIJ: dyrk1a in complex with hg-8-60-1 (10.1021/ACS.JMEDCHEM.7B01847 )
- 6EIL: dyrk1a in complex with xmd8-49 (10.1021/ACS.JMEDCHEM.7B01847 )
- 1Z19: crystal structure of a lambda integrase(75-356) dimer bound to a coc' core site (10.1038/NATURE03657 )
- 1Z1B: crystal structure of a lambda integrase dimer bound to a coc' core site (10.1038/NATURE03657 )
- 6N7A: structure of the human jak1 kinase domain with compound 39 (10.1016/J.BMCL.2019.04.008 )
- 6A1G: crystal structure of human dyrk1a in complex with compound 32 (10.1016/J.BMCL.2018.09.010 )
- 3ZDI: glycogen synthase kinase 3 beta complexed with axin peptide and inhibitor 7d (10.1021/JM301575N )
- 1M6X: flpe-holliday junction complex (10.1016/S0022-2836(02)01370-0 )
- 1IR3: phosphorylated insulin receptor tyrosine kinase in complex with peptide substrate and atp analog (10.1093/EMBOJ/16.18.5572 )
- 1IRS: irs-1 ptb domain complexed with a il-4 receptor phosphopeptide, nmr, minimized average structure (10.1038/NSB0496-388 )
- 4JMH: crystal structure of synthetic protein in complex with double py peptide (10.1016/J.MOLCEL.2014.05.002 )
- 5TQ3: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
- 5TQS: phospholipase c gamma-1 c-terminal sh2 domain bound to a phosphopeptide derived from the receptor tyrosine kinase erbb2 (10.1021/ACS.BIOCHEM.7B00023 )
- 5Y86: crystal structure of kinase (10.1016/J.JMB.2018.04.001 )
- 1T8I: human dna topoisomerase i (70 kda) in complex with the poison camptothecin and covalent complex with a 22 base pair dna duplex (10.1021/JM049146P )
- 4DIT: crystal structure of gsk3beta in complex with a imidazopyridine inhibitor 29-feb-12 4dit 1 title
- 3CD3: crystal structure of phosphorylated human feline sarcoma viral oncogene homologue (v-fes) in complex with staurosporine and a consensus peptide (10.1016/J.CELL.2008.07.047 )
- 4YLL: crystal structure of dyrk1aa in complex with 10-bromo-substituted 11h- indolo[3,2-c]quinolone-6-carboxylic acid inhibitor 5t (10.1021/JM501994D )
- 4YLJ: crystal structure of dyrk1a in complex with 10-iodo-substituted 11h- indolo[3,2-c]quinoline-6-carboxylic acid inhibitor 5j (10.1021/JM501994D )
- 5LQ0: crystal structure of tyr24 phosphorylated annexin a2 at 2.9 a resolution (10.1016/J.STR.2017.06.001 )
- 5LQ2: crystal structure of tyr24 phosphorylated annexin a2 at 3.4 a resolution (10.1016/J.STR.2017.06.001 )
- 3TJC: co-crystal structure of jak2 with thienopyridine 8 (10.1021/JM200911R )
- 3TJD: co-crystal structure of jak2 with thienopyridine 19 (10.1021/JM200911R )
- 1P7D: crystal structure of the lambda integrase (residues 75-356) bound to dna (10.1016/S1097-2765(03)00268-5 )
- 2Z8P: structural basis for the catalytic mechanism of phosphothreonine lyase (10.1038/NSMB1329 )
- 2Z8C: phosphorylated insulin receptor tyrosine kinase in complex with (4- {[5-carbamoyl-4-(3-methylanilino)pyrimidin-2-yl]amino}phenyl)acetic acid (10.1002/PROT.22207 )
- 5HX8: jak1 complex with 4-[(4-aminocyclohexyl)amino]-3-(1h-benzimidazol-2- yl)-1h-pyridin-2-one (10.1016/J.BMCL.2016.02.035 )
- 1BM2: grb2-sh2 domain in complex with cyclo-[n-alpha-acetyl-l-thi alysyl-o-phosphotyrosyl-valyl-asparagyl-valyl-prolyl] (pkf273-791) (10.1021/JM9811007 )
- 1BMB: grb2-sh2 domain in complex with kpfy*vnvef (pkf270-974) (10.1021/JM9811007 )
- 4J71: crystal structure of gsk3b in complex with inhibitor 1r
- 3OB1: crystal structure of c-cbl tkb domain in complex with double phosphorylated spry2 peptide (10.1371/JOURNAL.PONE.0012819 )
- 2ZOQ: structural dissection of human mitogen-activated kinase erk1 (10.1016/J.BBRC.2008.10.127 )
- 4E7W: structure of gsk3 from ustilago maydis (10.1021/CB300128B )
- 2YU7: solution structure of the shp-1 c-terminal sh2 domain complexed with a tyrosine-phosphorylated peptide from nkg2a
- 5NP2: abl1 sh3 ptyr89/134 (10.1074/JBC.RA118.004732 )
- 2Q8Y: structural insight into the enzymatic mechanism of the phophothreonine lyase (10.1016/J.MOLCEL.2007.11.011 )
- 5C27: crystal structure of syk in complex with compound 2 (10.1002/CMDC.201500333 )
- 6OPG: phosphorylated erk2 with amp-pnp (10.1073/PNAS.1906824116 )
- 3ZUV: crystal structure of a designed selected ankyrin repeat protein in complex with the phosphorylated map kinase erk2 (10.1073/PNAS.1205399109 )
- 1EEO: crystal structure of protein tyrosine phosphatase 1b complexed with acetyl-e-l-e-f-ptyr-m-d-y-e-nh2 (10.1021/BI000319W )
- 1EEN: crystal structure of protein tyrosine phosphatase 1b complexed with acetyl-d-a-d-bpa-ptyr-l-i-p-q-q-g (10.1021/BI000319W )
- 1FBV: structure of a cbl-ubch7 complex: ring domain function in ubiquitin- protein ligases (10.1016/S0092-8674(00)00057-X )
- 4Y5W: transcription factor-dna complex (10.1073/PNAS.1611228113 )
- 4Y5U: transcription factor (10.1073/PNAS.1611228113 )
- 5H0E: crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor (s)-2-(((1r,4s)-4-(4-amino-5-(4-phenoxyphenyl)-7h-pyrrolo[2,3- d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanamide (10.1016/J.BMC.2017.05.053 )
- 4D0X: pyrrole-3-carboxamides as potent and selective jak2 inhibitors (10.1016/J.BMC.2014.06.025 )